ADEQUAN

Main information

  • Trade name:
  • ADEQUAN POLYSULPHATED GLYCOSAMINOGLYCAN INJECTION 250MG/ML
  • Pharmaceutical form:
  • PARENTERAL LIQUID/SOLUTION/SUSPENSION
  • Units in package:
  • 5x1mL Amp
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • ELANCO AUSTRALASIA

Documents

Localization

  • Available in:
  • ADEQUAN POLYSULPHATED GLYCOSAMINOGLYCAN INJECTION 250MG/ML
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • HORSE | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH PERFORMANCE HORSES | HORSES AT STUD | MARE | PACER | POL
  • Therapeutic area:
  • antiarthritic
  • Therapeutic indications:
  • DEGENERATIVE ASEPTIC JOINT DISEASE | TRAUMATIC DEGENERATIVE JOINT D
  • Product summary:
  • An aid in the treatment of traumatic and degenerative aseptic joint disease in horses.

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered but not available
  • Authorization number:
  • 36012/0501
  • Authorization date:
  • 05-06-2001
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

,..

ADEQUAN IA

NRA 36012

PAGE 1 OF 4

8.5.2001

VIAL LABEL

rnt)

PRESCRIPTION ANIMAL REMEDY

KEEP OUT OF REACH OF CHILDREN

FOR ANIMAL TREATMENT ONLY

ADEQUAN®

POLYSULPHATED GLYCOSAMINOGLYCAN INJECTION 250 mg/mL

BOEHRINGER

INGELHEIM

_---.....-0::----,.;

N.R.A.

APPROVED

LABEL

('TEXl')

Label

.~iff.?'?:L~§:t?;··l

Date:

.Q.$."?!~

...

¥P

...

\

Sign~wrEl:

.,,:'..~/I~H;;.J

"..

ADEQUAN IA

NRA 36012

PAGE

8.5.2001

CARTON LABEL

PRESCRIPTION ANIMAL REMEDY

KEEP OUT OF REACH OF CHILDREN

FOR ANIMAL TREATMENT ONLY

ADEQUAN®

POLSULPHATED GLYCOSAMINOGLYCAN INJECTION 250 mglmL

An aid in the treatment of traumatic and degenerative aseptic joint disease in

horses

5 x 1 mL ampoules

READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT.

Directions for use

Administer the contents of

1 ampoule

mL) by intra-articular injection into

the affected joint once weekly for five weeks.

The joint area must

be shaved,

cleansed and sterilised prior to administration to prevent joint infection.

MEAT WITHHOLDING PERIOD

2a/DAYS.

Disposal

Dispose of empty container by wrapping with paper and putting in garbage.

Store below 25°C (air conditioning)

360121

Batch No.:

Expiry Date:

Boehringer

Ingelheim

Janssen Pharmaceutica

ADEQUAN IA

NRA 36012

PAGE

8.5.2001

PACKAGING INSERT

PRESCRIPTION ANIMAL REMEDY

KEEP

OUT

OF REACH OF CHILDREN

FOR ANIMAL TREATMENT ONLY

ADEQUAN®

Polysulphated Glycosaminoglycan Injection 250 mglmL

Indication

Adequan" is for use as an aid in the treatment of traumatic and degenerative

aseptic joint disease in horses.

In healthy cartilage the synthesis and degradation of cartilage is in

equilibrium.

In traumatic and degenerative joint

disease this balance is shifted

towards increasing degradation.

This results in a loss of

mucopolysaccharides which are the basic building blocks of cartilage.

destruction of joint cartilage progresses unless the process is reversed.

Adsquan"

is similar to the mucopolysaccharides of cartilage and is

concentrated in cartilaginous tissue.

Adsquan"

exerts its activity by a biphasic mechanism involving stimulation of

cartilage and synovial

metabolism as well

as inhibition of degrading enzymes

which are responsible for joint deterioration.

Adequan" substantially improves cartilage ability to withstand stress and

helps to restore normal

joint function.

Directions for Use

After intra-articular injection,

reactions in the joint

may

occur after the

first,

or occasionally after further injections.

Should an acute

inflammation occur,

withhold further injections.

If signs or symptoms of hypersensitivity occur,

the treatment must be

discontinued.

Due to the anticoagulant effect of Adequan®, treatment should not be

given in the presence of pathologically increased bleeding-risks or in

case of advanced renal or hepatic disease.

Administer the contents of

1 ampoule

mL) by intra-articular injection into

the affected joint once weekly for five weeks.

".

ADEQUAN IA

NRA 36012

PAGE 4 OF 4

8.5.2001

The joint

area must be shaved,

cleansed and sterilised prior to administration

to prevent,.joint infection.

In the presence of active joint inflammation,

prior to concomitant therapy with

a suitable anti-inflammatory agent should be used.

The anti-inflammatory

treatment should be discontinued as soon as possible since steroidal

non-steroidal

anti-inflammatory agents contribute to the degradation of

cartilage.

MEAT WITHOLDING PERIOD 28 DAYS.

Drug interactions

Adequan" will

increase the action of anticoagulant preparations due to its

structural

relationship to herapin.

When Adequan" is mixed with local

anaesthetics in concentrations over 1

with corticosteroid crystalline suspensions,

sedimentation may occur.

Disposal

Dispose of empty container by wrapping with paper and putting in garbage.

Storage

Store below 25°C (air conditioning)

Distributed by

Boehringer Ingelheim Pty Limited

Vetmedica Division

85 Waterloo Road

NORTH RYDE

NSW 2113

Janssen Pharmaceutica

6-1-2019

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

Lupin Pharmaceuticals, Inc. is voluntarily recalling 5 lots of Ceftriaxone for Injection, USP, 250mg, 10 lots of Ceftriaxone for Injection, USP, 500mg, 24 lots of Ceftriaxone for Injection, USP, 1g and 3 lots of Ceftriaxone for Injection, USP 2g, to the hospital/physician level. The products have been found to contain visual grey particulate matter in reconstituted vials.

FDA - U.S. Food and Drug Administration

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

31-7-2018

Public Notification: Black Rhino 25000 contains hidden drug ingredient

Public Notification: Black Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Black Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Krazzy Rhino 25000 contains hidden drug ingredient

Public Notification: Krazzy Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Krazzy Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Gold Rhino 25000 contains hidden drug ingredient

Public Notification: Gold Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Gold Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

31-7-2018

Public Notification: Platinum Rhino 25000 contains hidden drug ingredient

Public Notification: Platinum Rhino 25000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Platinum Rhino 25000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

10-7-2018

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

Preventieve HIV-remmers (PrEP) worden verstrekt voor een periode van vijf jaar

PrEP wordt binnen een onderzoekssetting voor een periode van vijf jaar verstrekt aan de hoogrisicogroep van mannen die seks hebben met mannen (MSM). Dat heeft minister Bruno Bruins (Medische Zorg) vandaag bekend gemaakt. Op basis van schattingen van het RIVM zullen ongeveer 6500 mannen hiervan gebruik gaan maken en kunnen hiermee  250 hiv-infecties per jaar worden voorkomen. Voor gebruikers gaat een eigen bijdrage gelden van maximaal 25%, dat komt overeen met ongeveer 12 euro per maand. Ook wordt hen gev...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

4-5-2018

Badger Botanicals Recalls Red Suma, Green Suma, Green Hulu 2, And Red Hulu 2 Kratom Supplements Because Of Possible Salmonella Health Risk

Badger Botanicals Recalls Red Suma, Green Suma, Green Hulu 2, And Red Hulu 2 Kratom Supplements Because Of Possible Salmonella Health Risk

Badger Botanicals, LLC of Springville, Utah is recalling Green Suma, Red Suma, Green Hulu 2, and Red Hulu 2 kratom dietary supplements sold directly to consumers via the company website from January 1st, 2018 to April l 12th, 2018 in pouches of 250g, because it has the potential to be contaminated with Salmonella.

FDA - U.S. Food and Drug Administration

15-1-2014

Revocation of wholesale distribution and manufacturing authorisations granted to Singad Pharma ApS

Revocation of wholesale distribution and manufacturing authorisations granted to Singad Pharma ApS

On 20 December 2013 and on 10 January 2014, the Danish Health and Medicines Authority decided to revoke the section 39 authorisations for wholesale distribution and manufacturing of medicinal products with the authorisation IDs 25081 and 25082 granted to Singad Pharma ApS (company number 255894).

Danish Medicines Agency

10-12-2018

EU/3/17/1906 (PTC Therapeutics International Limited)

EU/3/17/1906 (PTC Therapeutics International Limited)

EU/3/17/1906 (Active substance: Recombinant adeno-associated viral vector serotype 5 carrying the gene for the human frataxin protein) - Transfer of orphan designation - Commission Decision (2018)8634 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002509

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1786 (PTC Therapeutics International Limited)

EU/3/16/1786 (PTC Therapeutics International Limited)

EU/3/16/1786 (Active substance: Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein) - Transfer of orphan designation - Commission Decision (2018)8630 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002507

Europe -DG Health and Food Safety

10-12-2018

EU/3/16/1651 (PTC Therapeutics International Limited)

EU/3/16/1651 (PTC Therapeutics International Limited)

EU/3/16/1651 (Active substance: Recombinant adeno-associated viral vector serotype 9 carrying the gene for the human E6-AP ubiquitin protein ligase) - Transfer of orphan designation - Commission Decision (2018)8632 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002508

Europe -DG Health and Food Safety

28-11-2018

PHEBURANE (Eurocept International BV)

PHEBURANE (Eurocept International BV)

PHEBURANE (Active substance: Sodium Phenylbutyrate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)8043 of Wed, 28 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2500/T/20

Europe -DG Health and Food Safety

30-10-2018

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Akcea Therapeutics UK Ltd)

EU/3/14/1250 (Active substance: Phosphorothioate oligonucleotide targeted to transthyretin) - Transfer of orphan designation - Commission Decision (2018)7282 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/098/13/T/01

Europe -DG Health and Food Safety

29-10-2018

Replagal (Shire Human Genetic Therapies AB)

Replagal (Shire Human Genetic Therapies AB)

Replagal (Active substance: Agalsidase alfa) - Centralised - Yearly update - Commission Decision (2018)7250 of Mon, 29 Oct 2018

Europe -DG Health and Food Safety

3-7-2018

Samsca (Otsuka Pharmaceutical Europe Ltd)

Samsca (Otsuka Pharmaceutical Europe Ltd)

Samsca (Active substance: tolvaptan) - Centralised - 2-Monthly update - Commission Decision (2018) 4250 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/980/II/31

Europe -DG Health and Food Safety

6-6-2018

Stocrin (Merck Sharp and Dohme B.V.)

Stocrin (Merck Sharp and Dohme B.V.)

Stocrin (Active substance: efavirenz) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3689 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/250/T/113

Europe -DG Health and Food Safety

23-4-2018

Mylotarg (Pfizer Limited)

Mylotarg (Pfizer Limited)

Mylotarg (Active substance: gemtuzumab ozogamicin) - New authorisation - Commission Decision (2018)2504 of Mon, 23 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4204

Europe -DG Health and Food Safety